Lanfix

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lanfix

Property Description
Active Ingredient Cefixime (often as Trihydrate)
Form Tablet, Capsule, Chewable Tablet, Oral Suspension
Pharmacological Class Third-Generation Cephalosporin Antibiotic
Common Use Treating bacterial infections caused by susceptible organisms
Origin Semi-synthetic beta-Lactam compound

What Type of Medicine is Lanfix and What Does it Contain?

Lanfix is a prescription-only antibiotic whose primary active substance is Cefixime, a semi-synthetic compound. It belongs to the cephalosporin family, specifically classified as a third-generation cephalosporin antibiotic. This classification denotes its effectiveness against a broad spectrum of bacterial infections compared to many earlier generations. Cefixime is used as an anti-infective agent against susceptible isolates.

The core component, Cefixime, may be presented as a single-agent product or combined with Clavulanic Acid in specific Lanfix formulations. The inclusion of Clavulanic Acid serves as a beta-lactamase inhibitor, which is key to preserving the Cefixime from being deactivated by destructive bacterial enzymes, thus expanding the drug's range of action against certain resistant strains.


Physical Form and General Therapeutic Purpose

Lanfix is manufactured exclusively for oral administration and is available in several physical presentations, including tablets, capsules, chewable tablets, and a powder for oral suspension (liquid). The range of dosage forms is specifically designed to facilitate administration across different patient populations, including pediatric patients who may require the liquid suspension. The general therapeutic purpose of Lanfix is to act as a bactericidal agent, meaning it achieves the elimination of bacteria by fatally disrupting the synthesis of their essential cell walls. Cefixime is used because of its ability to kill bacteria and stop infection progression.

What side effects are possible with Lanfix?

Possible Side Effects and Safety Information

Lanfix (Cefixime) may be associated with a range of adverse reactions, primarily affecting the gastrointestinal and nervous systems. It is crucial to be aware of all documented side effects and safety restrictions.

Common Adverse Reactions

The most frequently reported side effects are categorized as common and generally involve:

  • Gastrointestinal Disturbances: Nausea, vomiting, diarrhea, stomach pain, indigestion, and flatulence.
  • Nervous System Disorders: Headache and dizziness.

Clinically Significant and Serious Adverse Reactions

Although rare, certain reactions require immediate medical attention as they are considered serious and clinically significant:

  • Severe Hypersensitivity Reactions (e.g., Anaphylaxis/Shock): Manifested by severe rash, itching, swelling (angioedema), or difficulty breathing. The use of Lanfix is contraindicated in patients with a history of shock or hypersensitivity to cephalosporins.
  • Hematologic, Renal, and Hepatic Effects: Potential for severe dysfunction in the blood, kidneys, or liver.

Population-Specific Safety Considerations and Restrictions

Specific caution is advised for certain patient populations:

  • Hypersensitivity History: Caution is required in patients with a history of allergy, particularly to penicillin antibiotics, due to the risk of cross-hypersensitivity.
  • Renal/Liver Impairment: The drug must be used with caution, and dose adjustments may be necessary for patients with severe renal or liver impairment.
  • At-Risk Groups for Vitamin K Deficiency: Close monitoring is necessary for the elderly, individuals with poor oral nutrition, or those in a weakened state due to the potential risk of Vitamin K deficiency symptoms.
  • Interactions: Lanfix may decrease the effectiveness of oral contraceptives and requires cautious use with certain blood thinners.

Overdose and Emergency Response

Lanfix Overdose and when to seek help

The regulatory information for Lanfix (Cefixime) details potential severe manifestations associated with an overdose, including risks to the Central Nervous System (CNS).

Overdose Scope Official Regulatory Statement
Documented Manifestations: Explicit risk of encephalopathy, which may involve symptoms such as confusion, impairment of consciousness, movement disorders, and convulsions (seizures).
Population Risk Factor: The risk of severe CNS effects is heightened particularly in the presence of renal impairment or altered kidney function.
Emergency Action: Patients experiencing life-threatening symptoms such as seizures must seek immediate medical attention.

Management and Constraints

Overdose Constraint Official Regulatory Statement
Antidote Availability: No specific antidote exists for Cefixime overdose.
Supportive Measures: Management is based on general supportive measures and symptomatic treatment. Gastric lavage may be indicated as a procedural step.
Removal Efficacy: The drug is not removed from the circulation in significant quantities by dialysis, including haemodialysis or peritoneal dialysis.

Connection to the overall overdose profile: The official regulatory documents define the Lanfix overdose profile primarily by the risk of Central Nervous System (CNS) toxicity, specifically encephalopathy, and mandate that patients experiencing severe manifestations must seek immediate medical attention. The profile emphasizes that no specific antidote exists and the drug’s clearance cannot be effectively enhanced by dialysis. Furthermore, regulatory sources explicitly flag renal impairment as a condition that increases the risk of severe overdose consequences.

Therapeutic Uses of Lanfix

Quick Facts: Therapeutic Domains

  • Respiratory Infections: Used to address certain infections of the airways, such as bronchitis and pneumonia, when caused by susceptible bacteria.
  • Urinary Tract Infections (UTIs): May help resolve uncomplicated infections in the urinary tract.
  • Ear, Nose, and Throat: Used to manage conditions like otitis media (middle ear infection), pharyngitis, and tonsillitis.
  • Gonorrhea: Could be an option for treating uncomplicated cervical or urethral gonorrhea.

What Lanfix Treats: Main Uses and Benefits

Lanfix is a prescription medication used to address various infections caused by susceptible bacteria in both adults and pediatric patients (aged six months and older). It functions by helping to control the growth of the harmful organisms responsible for the infection.

Lanfix is typically prescribed for infections of the respiratory tract, including acute exacerbations of chronic bronchitis and pneumonia. It is an option used in the treatment of uncomplicated urinary tract infections and is also utilized for infections in the ear, nose, and throat, such as otitis media and tonsillitis. Furthermore, Lanfix may be used to treat uncomplicated gonorrhea (cervical/urethral infections).

This medication should only be used to treat infections that are confirmed or strongly suspected to be caused by bacteria, as it will not work against viral conditions like the common cold or flu.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Lanfix

This section describes the official population eligibility and non-eligibility information for Lanfix (Cefixime) as documented in government regulatory sources, strictly excluding dosing and therapeutic details.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and adolescents, and pediatric patients aged six months and older, are eligible for use under standard labeled conditions.
Populations for whom use is contraindicated Individuals with a documented allergy to Cefixime or any antibiotic in the cephalosporin class are strictly ineligible. This includes a history of severe beta-lactam allergy (e.g., penicillin).
Populations for whom use is not established The safety and efficacy of Lanfix have not been established in infants younger than six months of age.

Condition-Specific Eligibility Rules

Category Regulatory Wording for Restriction
Organ Function Patients with marked renal impairment (impaired renal function) require eligibility review, as the official label mandates a dose modification. Use in pediatric patients with renal insufficiency is often not recommended.
Comorbidity Caution is advised for patients with a history of colitis or severe gastrointestinal disease. The chewable tablet formulation is unsuitable for patients with phenylketonuria (PKU).
Reproductive Status Use during pregnancy is permitted only if clearly needed. For nursing mothers, official documentation advises considering temporary discontinuation of nursing during treatment.

Resulting Eligibility Structure

Official regulatory documents establish who can and cannot use Lanfix by creating absolute contraindications based on allergy, imposing a non-established use status for infants, and mandating conditional use restrictions related to organ function and reproductive status. This framework defines the eligible population according to the official prescribing information.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Lanfix (Cefixime) interactions are officially documented in regulatory sources and primarily involve pharmacokinetic changes in plasma concentration and pharmacodynamic effects on blood coagulation. The prescribing information details several specific interactions.

Documented Drug–Drug Interactions

Interacting Substance Officially Documented Interaction Outcome
Probenecid Increases Cefixime plasma levels (AUC and Cmax) due to inhibition of renal tubular secretion.
Oral Anticoagulants (e.g., Warfarin) Associated with a prolongation of the Prothrombin Time (PT), which is a documented pharmacodynamic effect.
Carbamazepine Co-administration has been observed to result in increased plasma concentrations of Carbamazepine.

Interaction with Food

Absorption kinetics differ based on the product formulation. Food ingestion is documented to slow the rate of absorption of the Cefixime oral suspension, resulting in a lower maximum plasma concentration (Cmax). However, the total extent of absorption (AUC) remains unchanged. In contrast, the absorption rate and extent of Cefixime from the tablet formulation are not significantly affected by co-administration with food. No mandatory timing separation rules are documented for co-administered medicines, and there are no official contraindications based purely on interaction risk.

Mechanism of Action

Lanfix is a combination product composed of Cefixime and Clavulanic Acid, which function through distinct but complementary mechanistic domains to exert antibacterial activity.


Inhibition of Bacterial Cell Wall Synthesis

This domain involves the action of Cefixime, a beta-lactam antibiotic. Cefixime acts by binding covalently to Penicillin-Binding Proteins (PBPs) inside susceptible bacteria. These PBPs are transpeptidases essential for the final cross-linking stage of peptidoglycan synthesis. Modifying these molecular steps disrupts the structural integrity of the bacterial cell wall, ultimately leading to osmotic lysis and cell death. This results in a bactericidal physiological effect.


Counteracting beta-Lactamase Resistance

This domain is addressed by Clavulanic Acid, which acts as an irreversible beta-lactamase inhibitor. Many resistant bacteria secrete beta-lactamase enzymes that hydrolyze the beta-lactam ring of Cefixime, rendering it inactive before it can reach PBPs. Clavulanic Acid engages mechanisms that bind tightly to and suppress the hydrolytic activity of these beta-lactamase enzymes. This preserves the functional concentration of Cefixime, allowing it to access and bind to its PBP target site.

Dosage and Administration Information

How Lanfix is Used: Administration Guidelines

Lanfix (Cefixime) is strictly for oral administration and is available in forms including tablets, capsules, and a powder for oral suspension. The general principle of usage is defined by specific dosage, duration, and administration rules.


Standard Dosage and Frequency

The typical adult regimen for general infections is a total daily dose of 400 mg, which may be administered either as a single dose once daily or in two divided doses of 200 mg every 12 hours. For children aged six months and older, the prescribed dose is 8 mg/kg/day, also available as a single or divided dose, with the total daily dose not exceeding 400 mg.

Usage Scenario Dosing Rule Course Duration
General Infections 400 mg daily (Adults) Typically 7 to 14 days
S. pyogenes Infections Standard daily dose Minimum of 10 days
Uncomplicated Gonorrhea Single oral dose of 400 mg Single dose regimen

Administration Requirements

Lanfix may be taken without regard to meals (with or without food). The oral suspension must be reconstituted from powder, shaken well before measuring each dose, and measured using a calibrated device for accuracy. It is specified that the tablets and suspension are not considered interchangeable for all conditions, meaning one should not be substituted for the other.

Population Adjustments

For adult patients with severe renal impairment (creatinine clearance less than 20 mL/min), the dosage must be reduced to 200 mg once daily. Dosing for older adults is the same as the standard adult dose, but their renal function should be assessed prior to treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lanfix (Cefixime)

The research exploring its use in several types of bacterial infections draws from a variety of study designs including Randomized Controlled Trials (RCTs) and systematic reviews cited in regulatory and scientific publications. The findings describe group patterns and contribute to the broader evidence landscape, but they do not provide individual predictions. This summary is derived from authoritative governmental and peer-reviewed scientific sources.


Evidence for Use in Infections of the Urinary Tract and Throat

The evidence for exploring uncomplicated infections in these areas is largely built upon clinical trials designed to assess outcomes over a short period.

Study Focus on Uncomplicated Urinary Tract Infections (UTIs)

Lanfix was studied for use in the treatment of acute, uncomplicated UTIs, which are conditions involving acute or disruptive episodes. Research primarily included short-term clinical trials that evaluated outcomes in adult outpatients and some children. The main outcomes research examined included the rate of bacteriological eradication (measurements related to the clearance of the specific causative bacteria) and the measurements of clinical change of outcomes related to physical discomfort.

Research on Pharyngitis and Tonsillitis

Lanfix was evaluated in clinical trials for managing bacterial infections of the throat, specifically those caused by susceptible strains of Streptococcus pyogenes. These studies focused on both pediatric and adult populations. The main outcomes research explored included measurements of bacteriological eradication and the tracking of measurements of clinical change defined by symptom changes. Findings help contextualize how patients reported their experience.


Evidence for Use in Respiratory and Middle Ear Infections

Study Focus on Acute Otitis Media (AOM)

Research exploring AOM, a condition involving periods of heightened symptoms, has primarily involved RCTs and large observational studies conducted in pediatric patients (children aged six months and older). The studies monitored outcomes such as the measurements of changes in physical discomfort (like ear pain) and measurements related to the eradication of susceptible bacteria. Most of the available data for pediatric patients relies on the suspension formulation.


Key Limitations and Areas of Uncertainty in the Research

A consistent limitation across the evidence base is the focus on short-term follow-up durations, meaning that the long-term effects are not fully established for most indications. For certain infections, such as gonorrhea, the evidence base is complicated by changing resistance patterns, which means that historical trial results may not fully reflect the current patterns of bacterial susceptibility under which the studies were conducted. Overall, comparative evidence is lacking for some patient subgroups.

Frequently Asked Questions (FAQ)

Common questions about Lanfix (FAQ)


Q: What is the main reason doctors prescribe Lanfix?

According to official product information, Lanfix is approved for use as an antibiotic to treat infections caused by specific susceptible bacteria. These include certain types of infections affecting the urinary tract, the throat (like pharyngitis), and the middle ear (acute otitis media). Regulatory documents categorize it as an anti-infective agent intended to eliminate bacteria and manage the progression of infection.


Q: How quickly should a person expect to feel the effects of Lanfix?

Official documents regarding Lanfix focus on the drug's effectiveness in achieving clinical endpoints, such as rates of bacterial eradication during studies. They do not specify a typical or expected timeline for an individual patient to start noticing changes in their symptoms. Questions regarding an individual's progress are best addressed by a healthcare provider.


Q: How long does Lanfix usually stay in your system?

Regulatory information contains specific pharmacokinetic data, including the drug’s elimination half-life. This measurement describes the rate at which the concentration of the medication decreases in the bloodstream over time. This data is used by healthcare professionals to determine appropriate dosing schedules.


Q: Does Lanfix commonly cause weight gain or loss?

Weight gain or loss is not consistently listed among the common adverse reactions found in the official prescribing information for Lanfix. The most frequently reported side effects primarily involve the gastrointestinal and nervous systems.


Q: Can Lanfix affect sleep patterns?

Official prescribing information lists headache and dizziness as common side effects affecting the nervous system. However, the regulatory documentation does not specifically list sleep pattern disturbances, such as insomnia or vivid dreams, as commonly reported adverse reactions.


Q: What happens if I miss a dose of Lanfix?

Official administration rules provide guidance on this situation. If a dose is missed, it should be taken as soon as it is remembered, unless it is already almost time for the next scheduled dose. Specific details on managing the timing of a prescribed medication are typically found in the patient counseling information.


Q: Is it common to feel tired when starting Lanfix?

Fatigue or tiredness is not listed among the most frequent adverse reactions reported for Lanfix. However, official regulatory documentation does describe fatigue as a side effect observed during certain clinical experiences with the drug.


Q: Does Lanfix interact with over-the-counter pain medications like ibuprofen?

Official interaction documents specify known drug-drug interactions with substances such as Probenecid and certain blood thinners. The official documentation does not list a specific documented interaction with over-the-counter NSAID pain relievers, such as ibuprofen.


Q: Can I take Lanfix if I am also taking vitamins or herbal supplements?

Official prescribing information focuses on documented drug-drug interactions with other prescription medications. The documentation does not contain specific study data or comprehensive guidance regarding co-administration with all types of vitamins or herbal supplements.


Q: Are there any known food or drink restrictions when taking Lanfix?

Official guidance on administration clarifies that Lanfix can be taken without regard to meals. Food is documented to slow the rate of absorption for the liquid suspension, but not for the tablet formulation. There are no specific restrictions on common foods or drinks documented in the official interaction sections.


Q: What are the typical warnings about alcohol use with Lanfix?

The official documentation and safety information for Lanfix does not include a specific warning or contraindication regarding the use of alcohol during treatment.


Q: Is Lanfix safe for people with kidney problems?

Official prescribing information details that for adult patients with severe renal impairment, a modification to the dose is required. The eligibility map establishes that use in pediatric patients with renal insufficiency is often not recommended.


Q: Is Lanfix appropriate for people with liver conditions?

Official safety information advises caution regarding the use of Lanfix in individuals with existing liver impairment. This caution is advised due to the potential for severe effects on the liver (hepatic effects) that have been reported in regulatory documentation.


Q: What does it mean that Lanfix has a 'boxed warning'?

A Boxed Warning (also known as a black box warning) is a specific designation used by the FDA to call attention to serious or life-threatening adverse events that a drug may carry. The official labeling for Lanfix does not contain this specific type of warning.


Q: Is Lanfix a drug that requires blood monitoring?

Official documentation specifies that close patient monitoring is necessary for specific at-risk groups, such as the elderly or those with poor oral nutrition. This is due to the potential risk of Vitamin K deficiency symptoms which are a documented safety consideration.


Q: What should I do if I think I am having an allergic reaction to Lanfix?

Official warnings state that signs of a severe allergic reaction include difficulty breathing, severe rash, and swelling (angioedema). If any of these signs occur, regulatory guidance strongly advises discontinuing treatment immediately and seeking emergency medical services.


Q: Is it possible to develop a dependency on Lanfix?

Lanfix is classified as a cephalosporin antibiotic, an anti-infective agent. It is not classified as a controlled substance, and the official regulatory documentation does not indicate that the drug carries a risk of dependency or addiction.


Q: What type of study was the key clinical evidence for Lanfix?

The core evidence that supports the approved uses of Lanfix is derived from clinical trials described in regulatory documentation. These studies include Randomized Controlled Trials (RCTs) which are designed to assess the drug's efficacy against specific susceptible bacterial isolates.


Q: Is there a generic version of Lanfix available?

Yes, the active ingredient in Lanfix, Cefixime, is available in generic formulations. These generic versions have been reviewed and approved by regulatory authorities for use.


Q: What is the difference between the different Lanfix strengths (e.g., 10mg vs 20mg)?

Official documents state that different strengths and dosage forms, such as tablets and suspensions, are manufactured to provide flexible dosing options. This flexibility allows healthcare professionals to accurately determine the correct amount of medicine needed based on the patient's age, weight, and clinical condition.


Q: Why is Lanfix not recommended for people with Condition Z?

The regulatory eligibility map establishes clear boundaries for use, based on safety and efficacy data. Absolute contraindications exist for individuals with a known allergy to the drug or cephalosporin class. Furthermore, restrictions or required dose modifications apply to people with severe renal impairment, a history of colitis, or phenylketonuria (PKU) when using the chewable formulation.


Q: Do I need a special blood test before starting Lanfix?

Official guidance emphasizes the importance of assessing kidney function before starting treatment, particularly for patients who already have renal impairment. However, the prescribing information does not mandate specific routine blood tests for all patients prior to the start of treatment.


Q: Can Lanfix affect fertility in men or women?

Non-clinical studies, typically conducted in animals and summarized in regulatory documents, examined the effects of Lanfix on reproductive potential. These studies did not suggest that the medication has an effect on fertility in men or women.


Q: Why is Lanfix used for two completely different conditions?

Lanfix is officially defined as a broad-spectrum antibiotic. Official documents explain that its mechanism of action—disrupting the cell wall of susceptible bacteria—allows it to be used against various types of infections that are caused by a range of specific susceptible organisms.


Q: What is the official safety classification of Lanfix?

Lanfix is officially classified by regulatory bodies as a third-generation cephalosporin antibiotic. This classification defines its chemical structure, its pharmacological class, and its expected spectrum of activity against certain susceptible bacteria.


Q: Can Lanfix cause dizziness or problems with driving?

Official safety information lists dizziness as a common adverse reaction affecting the nervous system. Regulatory guidance advises that if dizziness is experienced, the patient's ability to drive or operate machinery may be affected.


Q: What does official guidance say about stopping Lanfix treatment?

Official patient counseling guidance emphasizes that the full prescribed course of treatment is important for managing the infection. This instruction applies even if symptoms begin to improve before the medication is finished, unless a healthcare professional advises otherwise.


Q: What are the signs that Lanfix might be starting to work?

Official documents state that the goal of Lanfix treatment is two-fold: the eradication of susceptible bacteria and achieving clinical improvement. Clinical improvement is measured by a reduction in the signs and symptoms associated with the infection being treated.


Q: Is it normal to have vivid dreams while taking Lanfix?

Official documentation lists headache and dizziness as common effects on the nervous system, but does not specifically list sleep pattern disturbances or vivid dreams as commonly reported adverse reactions.


Q: Does the time of day I take Lanfix matter?

The official administration guidance for Lanfix provides flexibility in timing, allowing it to be taken either as a single dose once daily or in two divided doses. Furthermore, it can be taken without regard to meals.


Q: What is the significance of the patent expiring for Lanfix?

The expiration of a drug patent is the regulatory event that allows other manufacturers to seek approval to produce generic versions of the medicine. This process occurs only after the generic formulation has received official regulatory approval for use.


Q: Are there reports of Lanfix interacting with caffeine?

Official drug interaction documents list known interactions with specific prescription drugs like Probenecid and certain anticoagulants. The regulatory information does not contain a specific documented interaction or warning regarding the consumption of caffeine.


Q: Does taking Lanfix affect routine lab results (like cholesterol)?

Regulatory warnings state that Lanfix may cause false-positive results in certain laboratory tests. Specifically, this effect has been noted for urine glucose tests that use a cupric sulfate solution.


Q: Is Lanfix an opioid?

Lanfix is officially classified as a cephalosporin antibiotic. This means it belongs to a class of anti-infective agents used to treat bacterial infections, and it is not classified as an opioid drug.


Q: How do doctors monitor if Lanfix is working?

Based on the design of clinical studies, the effectiveness of Lanfix is primarily assessed by measuring two key outcomes. These include the clearance of the target bacteria (bacteriological eradication) and tracking measurements of clinical change related to the patient’s symptoms.


Q: Does Lanfix have any known contraindications with common vaccines?

Official drug interaction documentation, which lists documented interactions, does not contain any known contraindications or specific warnings regarding the co-administration of Lanfix with common vaccines.

How should Lanfix be stored and disposed of?

How to Store and Dispose of Lanfix

Lanfix (Cefixime) must be stored strictly according to regulatory requirements, and all forms must be kept out of the reach of children.

Storage Conditions

Dosage Form Mandatory Storage Conditions
Tablets/Capsules/Powder Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Keep tightly closed, away from moisture, direct light, and heat. Do not freeze.
Reconstituted Suspension May be stored at room temperature or under refrigeration (2 C to 25 C). The container must be kept tightly closed.

Stability and Disposal

The reconstituted liquid suspension has a maximum stability period of 14 days and any unused portion must be thrown away after this time. Do not keep outdated medicine. Patients are instructed to ask a healthcare professional how to correctly dispose of unused or expired Lanfix; the product should not be allowed to enter drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lanfix found in:

A-Z Index: